Abelzeta Files Bispecific CAR Patent for CD20 and BCMA
Summary
Abelzeta Inc. filed US Patent Application US20260108556A1 covering bispecific chimeric antigen receptors (CARs) that simultaneously target CD20 and BCMA antigens. The CAR constructs comprise an anti-CD20 scFv, an anti-BCMA scFv, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The filing was submitted on October 13, 2025, under Application No. 19356548, and names six inventors: Yihong Yao, Jiaqi Huang, Shigui Zhu, Xin Yao, Xiaobing Luo, and Yutian Wei. The claimed compositions are directed toward treating autoimmune disorders and cancer.
“The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
Abelzeta Inc. filed a bispecific CAR patent application with the USPTO covering constructs that co-target CD20 and BCMA via dual scFv binding domains, with applications for autoimmune disorders and cancer. The application, assigned US20260108556A1 and published April 23, 2026, claims priority to Application No. 19356548 filed October 13, 2025. Six inventors are named: Yihong Yao, Jiaqi Huang, Shigui Zhu, Xin Yao, Xiaobing Luo, and Yutian Wei.
Pharmaceutical and biotechnology companies developing CAR-T or bispecific immunotherapy platforms should review this filing for potential freedom-to-operate implications, particularly in oncology and autoimmune indications where CD20 (B-cell markers) and BCMA (B-cell maturation antigen) are established therapeutic targets. Competitors with existing CAR programs targeting either antigen alone may need to assess whether combination or bispecific approaches fall within Abelzeta's claimed scope.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMA
Application US20260108556A1 Kind: A1 Apr 23, 2026
Assignee
ABELZETA INC.
Inventors
Yihong YAO, Jiaqi HUANG, Shigui ZHU, Xin YAO, Xiaobing LUO, Yutian WEI
Abstract
The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
CPC Classifications
A61K 35/17 A61K 40/11 A61K 40/15 A61K 40/31 A61K 40/4202 A61K 40/4215 A61K 40/4221 A61K 40/4224 A61P 35/00 A61P 37/02 A61P 37/06 C07K 16/2878 C07K 16/2887 C12N 5/0636 A61K 2239/13 A61K 2239/21 A61K 2239/22 A61K 2239/29 C07K 2317/31 C07K 2317/53 C07K 2317/622 C07K 2319/03 C12N 2510/00
Filing Date
2025-10-13
Application No.
19356548
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.